← Leaderboards
Robert C Doebele
University Of Colorado Denver
$1,973,721
Attributed
$1,973,721
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2016–20$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,573,721 · 2
By mechanism
P50$4,600,000 · 1
R01$1,973,721 · 1
Top collaborators
- Paul A Bunn2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- York E Miller$6,348,289
- Paul A Bunn$21,859,370
- Holly R Wyatt$4,032,896
- Raphael A. Nemenoff$15,000,654
- Joshua M Thurman$14,218,696
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPublishingEpidermal Growth Factor ReceptorNon-Small-Cell Lung CarcinomaCancer PatientMalignant Neoplasm Of LungMortalitySignal TransductionClinical TrialsInsightGene FusionCancer EtiologyIn VitroInhibitor/AntagonistKinase InhibitorDrug TargetingCancer CellDrug ResistanceEgfr GeneDisease ProgressionChromosomal TranslocationCellsCell LineBreast Cancer Cell
Grant awards (7)
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.$349,477
R01 · FY2020 · CA · contact PI
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.$338,993
R01 · FY2019 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2018 · CA
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.$422,586
R01 · FY2018 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2017 · CA
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.$428,571
R01 · FY2017 · CA · contact PI
The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.$434,094
R01 · FY2016 · CA · contact PI